Stockscreener 앱 받기
147.90
6.04%
8.42
시간 외 거래:
148.54
0.64
+0.43%
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines rises as FDA clears expanded access pathway for daraxonrasib - Quiver Quantitative
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates? - TradingView
Revolution Medicines Files Patent Infringement Lawsuit Against Erasca - HarianBasis.co
Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity - Insider Monkey
Revolution Medicines Inc. (RVMD): Billionaire Tom Steyer Remains Bullish on This Stock - Yahoo Finance
Jennison Associates LLC Takes $24.31 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines' Pancreatic-Cancer Drug Cleared for Expanded Access - Moomoo
US FDA authorizes early access to Revolution's pancreatic cancer pill - Reuters
Revolution Medicines Advances Pancreatic Cancer Treatment with Daraxonrasib - GuruFocus
Revolution Medicines (RVMD) Gains FDA Approval for Daraxonrasib in Pancreatic Cancer - GuruFocus
Revolution Medicines receives FDA early access authorization for pancreatic cancer pill - Investing.com Canada
Revolution Medicines (RVMD) Advances with FDA Approval for Expan - GuruFocus
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $215 - Moomoo
The U.S. Food and Drug Administration (FDA) has issued a "safe to proceed" letter to Revolution Medicines, Inc., approving the initiation of an expanded access program for its investigational drug Daraxonrasib for the treatment of pancreatic cancer patients. - Bitget
Revolution Medicines' cancer drug made available in U.S. - Seeking Alpha
F.D.A. grants early access to Revolution Medicines promising drug Daraxonrasib for pancreatic cancerNYT - marketscreener.com
Revolution Medicines, Inc. $RVMD Shares Bought by Vanguard Group Inc. - MarketBeat
First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know - Pancreatic Cancer Action Network
Revolution Medicines Data Updates Refocus Investor Attention On RAS Pipeline Potential - simplywall.st
Revolution Medicines (RVMD) price target increased by 10.02% to 136.84 - MSN
Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy - MSN
Revolution Medicines’ Anthony Mancini sells $413k in shares By Investing.com - Investing.com India
Revolution Medicines’ Anthony Mancini sells $413k in shares - Investing.com
Revolution Medicines (RVMD) insider sells 3,120 shares after exercising options - Stock Titan
Revolution Medicines sets May 6 webcast for Q1 results, corporate update - Stock Titan
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Universal Beteiligungs und Servicegesellschaft mbH Has $5.23 Million Stake in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines has a market cap of $29 billion and generates no revenue. Here's why its valuation may not be as ridiculous as it seems - MSN
Pictet Asset Management Holding SA Reduces Stake in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines, Inc. $RVMD Shares Bought by UBS Group AG - MarketBeat
Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday - MarketBeat
RVMD Technical Analysis | Trend, Signals & Chart Patterns | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines (RVMD) price target increased by 29.89% to 177.75 - MSN
Revolution Medicines plans $1B combined equity and convertible note offerings - MSN
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off. - Barron's
RVMD Stock Rallies As Daraxonrasib Data Ignite Wall Street - StocksToTrade
RVMD Stock Rallies As Daraxonrasib Data Fuels Bullish Re‑Rating - timothysykes.com
Biotech Momentum Sparks Attention Beyond Nasdaq Composite - Kalkine Media
Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates - Yahoo Finance
There’s a Revolution in Cancer. But Can Big Pharma Afford It? - WSJ
Revolution Medicines (NASDAQ:RVMD) Shares Gap Up After Analyst Upgrade - MarketBeat
RVMD Stock Climbs As Daraxonrasib Data Ignite Street Targets - StocksToTrade
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday? - Benzinga
High-flying Revolution Medicines threatens to sue a cancer drug competitor with licensed Chinese drug - The Business Journals
[ARS] Revolution Medicines, Inc. SEC Filing - Stock Titan
Revolution Medicines (NASDAQ:RVMD) Raised to Strong-Buy at Truist Financial - MarketBeat
Calamos Advisors LLC Takes $992,000 Position in Revolution Medicines, Inc. $RVMD - MarketBeat
RVMD Stock Price, Quote & Chart | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines Trial Updates Spark Fresh Interest In RAS Focused Pipeline - Yahoo Finance
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
RVMDW Price History for Revolution Medicines WT Stock - Barchart
Merck ends talks to buy Revolution Medicines, WSJ reports - MSN
Revolution Medicines (NASDAQ: RVMD) outlines 2026 virtual annual meeting votes - Stock Titan
[144] Revolution Medicines, Inc. SEC Filing - Stock Titan
Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems - The Motley Fool
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib - MSN
5.07%
자본화:
|
볼륨(24시간):